Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotran...
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Asan Medical Center, Seoul, Korea, Republic of
Tongji Hospital, Wuhan, Hubei, China
Asan Medical Center, Seoul, Korea, Republic of
Asan Medical Center, Seoul, Korea, Republic of
Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China
Wonkwag UH, Iksan, Jeollabukdo, Korea, Republic of
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
the Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China
the Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.